ESTRO Brachytherapy for Prostate Cancer 2018
Prognostic ‘risk’ groups: Low – Intermediate - High
Depending on: -
Extension of the tumour
- -
Initial PSA
Gleason Score
Low Risk
Intermediate Risk
High Risk
Stage: T1 or T2a,b Gleason Sum < 6 PSA < 10 ng/ml
StageT1 or T1-2 StageT1-2 Gleason Score 7 or Gleason 6 PSA < 10 PSA 10-20
StageT2c or T3 Gleason score ≥ 8 PSA > 20 ng/mL
Made with FlippingBook - Online catalogs